289 related articles for article (PubMed ID: 38785992)
1. Oncogenic Pathways and Targeted Therapies in Ovarian Cancer.
Lliberos C; Richardson G; Papa A
Biomolecules; 2024 May; 14(5):. PubMed ID: 38785992
[TBL] [Abstract][Full Text] [Related]
2. Drug-Resistant Epithelial Ovarian Cancer: Current and Future Perspectives.
Mehrotra M; Phadte P; Shenoy P; Chakraborty S; Gupta S; Ray P
Adv Exp Med Biol; 2024; 1452():65-96. PubMed ID: 38805125
[TBL] [Abstract][Full Text] [Related]
3. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
4. Recent advancements in therapeutic targeting of the Warburg effect in refractory ovarian cancer: A promise towards disease remission.
Tyagi K; Mandal S; Roy A
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188563. PubMed ID: 33971276
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer.
Guan L; Li Z; Xie F; Pang Y; Zhang C; Tang H; Zhang H; Chen C; Zhan Y; Zhao T; Jiang H; Jia X; Wang Y; Lu Y
J Exp Clin Cancer Res; 2020 Mar; 39(1):53. PubMed ID: 32293499
[TBL] [Abstract][Full Text] [Related]
6. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.
Deng J; Wang L; Chen H; Li L; Ma Y; Ni J; Li Y
Cancer Metastasis Rev; 2013 Dec; 32(3-4):535-51. PubMed ID: 23609751
[TBL] [Abstract][Full Text] [Related]
7. The Molecular Landscape Influencing Prognoses of Epithelial Ovarian Cancer.
Liu CL; Yuan RH; Mao TL
Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356623
[TBL] [Abstract][Full Text] [Related]
8. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.
Buechel M; Herzog TJ; Westin SN; Coleman RL; Monk BJ; Moore KN
Ann Oncol; 2019 May; 30(5):721-732. PubMed ID: 30887020
[TBL] [Abstract][Full Text] [Related]
9. Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
Koren Carmi Y; Mahmoud H; Khamaisi H; Adawi R; Gopas J; Mahajna J
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906729
[TBL] [Abstract][Full Text] [Related]
10. Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Smolle E; Taucher V; Petru E; Haybaeck J
Anticancer Res; 2014 Apr; 34(4):1519-30. PubMed ID: 24692678
[TBL] [Abstract][Full Text] [Related]
11. Targeting signaling pathways in epithelial ovarian cancer.
Smolle E; Taucher V; Pichler M; Petru E; Lax S; Haybaeck J
Int J Mol Sci; 2013 May; 14(5):9536-55. PubMed ID: 23644885
[TBL] [Abstract][Full Text] [Related]
12. Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer.
Konstantinopoulos PA; Matulonis UA
Hematol Oncol Clin North Am; 2018 Dec; 32(6):997-1010. PubMed ID: 30390770
[TBL] [Abstract][Full Text] [Related]
13. miR-211 facilitates platinum chemosensitivity by blocking the DNA damage response (DDR) in ovarian cancer.
Wang T; Hao D; Yang S; Ma J; Yang W; Zhu Y; Weng M; An X; Wang X; Li Y; Wu D; Tang J; Yang C; He Y; Zhang L; Jin X; Wang G; Li Z; Zheng T; Meng H; Feng Y; Li X
Cell Death Dis; 2019 Jun; 10(7):495. PubMed ID: 31235732
[TBL] [Abstract][Full Text] [Related]
14. Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer.
Guler E; Smith DA; Somarouthu B; Gujrathi R; Ramaiya NH; Tirumani SH
Abdom Radiol (NY); 2020 Mar; 45(3):828-841. PubMed ID: 31396642
[TBL] [Abstract][Full Text] [Related]
15. The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer.
Wambecke A; Ahmad M; Lambert B; Joly F; Poulain L; Denoyelle C; Meryet-Figuiere M
Gynecol Oncol; 2020 Mar; 156(3):726-733. PubMed ID: 31883617
[TBL] [Abstract][Full Text] [Related]
16. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies for treatment of recurrent ovarian cancer.
Grisham RN; Hyman DM; Iyer G
Clin Adv Hematol Oncol; 2014 Mar; 12(3):158-62. PubMed ID: 24927263
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Wu D; Lu P; Mi X; Miao J
Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
[TBL] [Abstract][Full Text] [Related]
19. CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer.
Nie S; Wan Y; Wang H; Liu J; Yang J; Sun R; Meng H; Ma X; Jiang Y; Cheng W
J Ovarian Res; 2021 Sep; 14(1):115. PubMed ID: 34474677
[TBL] [Abstract][Full Text] [Related]
20. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
